DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 878

[Docket No. FDA-2014-N-0107]

Medical Devices; General and Plastic Surgery Devices; Classification of the Absorbable Lung Biopsy Plug

AGENCY: Food and Drug Administration, HHS.

ACTION: Final order.

SUMMARY: The Food and Drug Administration (FDA) is classifying the absorbable lung biopsy plug into class II (special controls). The special controls that will apply to the device are identified in this order, and will be part of the codified language for the absorbable lung biopsy plug’s classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

DATES: This order is effective [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. The classification was effective on December 19, 2012.

FOR FURTHER INFORMATION CONTACT: Neel Patel, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 2532, Silver Spring, MD 20993-0002, 301-796-6274.

SUPPLEMENTARY INFORMATION:

I. Background

In accordance with section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(f)(1)), devices that were not in commercial distribution before May
2, 1976 (the date of enactment of the Medical Device Amendments of 1976), generally referred
to as postamendments devices, are classified automatically by statute into class III without any
FDA rulemaking process. These devices remain in class III and require premarket approval,
unless and until the device is classified or reclassified into class I or II, or FDA issues an order
finding the device to be substantially equivalent, in accordance with section 513(i), to a predicate
device that does not require premarket approval. The Agency determines whether new devices
are substantially equivalent to predicate devices by means of premarket notification procedures
in section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807) of the
regulations.

Section 513(f)(2) of the FD&C Act, as amended by section 607 of the Food and Drug
Administration Safety and Innovation Act (Public Law 112-144, July 9, 2012, 126 Stat. 1054),
provides two procedures by which a person may request FDA to classify a device under the
criteria set forth in section 513(a)(1). Under the first procedure, the person submits a premarket
notification under section 510(k) for a device that has not previously been classified and, within
30 days of receiving an order classifying the device into class III under section 513(f)(1), the
person requests a classification under section 513(f)(2). Under the second procedure, rather than
first submitting a premarket notification under section 510(k) and then a request for classification
under the first procedure, the person determines that there is no legally marketed device upon
which to base a determination of substantial equivalence and requests a classification under
section 513(f)(2). If the person submits a request to classify the device under this second
procedure, FDA may decline to undertake the classification request if FDA identifies a legally
marketed device that could provide a reasonable basis for review of substantial equivalence with
the device or if FDA determines that the device submitted is not of “low-moderate risk” or that
general controls would be inadequate to control the risks and special controls to mitigate the risks cannot be developed.

In response to a request to classify a device under either procedure provided by section 513(f)(2) of the FD&C Act, FDA will classify the device by written order within 120 days. This classification will be the initial classification of the device.

In accordance with section 513(f)(1) of the FD&C Act, FDA issued an order on March 19, 2009, classifying the Bio-Seal Lung Biopsy Tract Plug System into class III, because it was not substantially equivalent to a device that was introduced or delivered for introduction into interstate commerce for commercial distribution before May 28, 1976, or a device which was subsequently reclassified into class I or class II. On April 16, 2009, Angiotech submitted a request for classification of the Bio-Seal Lung Biopsy Tract Plug System under section 513(f)(2) of the FD&C Act. The manufacturer recommended that the device be classified into class II (Ref. 1).

In accordance with section 513(f)(2) of the FD&C Act, FDA reviewed the request in order to classify the device under the criteria for classification set forth in section 513(a)(1) of the FD&C Act. FDA classifies devices into class II if general controls by themselves are insufficient to provide reasonable assurance of safety and effectiveness but there is sufficient information to establish special controls to provide reasonable assurance of the safety and effectiveness of the device for its intended use. After review of the information submitted in the request, FDA determined that the device can be classified into class II with the establishment of special controls. FDA believes these special controls will provide reasonable assurance of the safety and effectiveness of the device.
Therefore, on December 19, 2012, FDA issued an order to the requester classifying the device into class II. FDA is codifying the classification of the device by adding 21 CFR 878.4755.

Following the effective date of this final classification order, any firm submitting a premarket notification (510(k)) for an absorbable lung biopsy plug will need to comply with the special controls named in this final order.

The device is assigned the generic name Absorbable Lung Biopsy Plug, and it is identified as a preformed (polymerized) absorbable lung biopsy plug intended to provide accuracy in marking a biopsy location for visualization during surgical resection and closure of pleural punctures associated with percutaneous, transthoracic needle lung biopsies. Upon deployment into the biopsy tract, the plug expands to fill the biopsy void and remains in place until resorbed.

FDA has identified the following risks to health associated specifically with this type of device, as well as the mitigation measures.

<table>
<thead>
<tr>
<th>Identified Potential Risk</th>
<th>Recommended Mitigation Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inability to deploy plug</td>
<td>Design and Material Characterization</td>
</tr>
<tr>
<td></td>
<td>Bench Testing</td>
</tr>
<tr>
<td></td>
<td>In Vivo Evaluation</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Delayed plug expansion</td>
<td>Design and Material Characterization</td>
</tr>
<tr>
<td></td>
<td>Bench Testing</td>
</tr>
<tr>
<td></td>
<td>In Vivo Evaluation</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Leakage around plug</td>
<td>Design and Material Characterization</td>
</tr>
<tr>
<td></td>
<td>Bench Testing</td>
</tr>
<tr>
<td></td>
<td>In Vivo Evaluation</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Plug migration (whole plug and/or fragments)</td>
<td>Design and Material Characterization</td>
</tr>
<tr>
<td></td>
<td>Bench Testing</td>
</tr>
<tr>
<td></td>
<td>In Vivo Evaluation</td>
</tr>
<tr>
<td>Identified Potential Risk</td>
<td>Recommended Mitigation Measure</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Procedural complications</td>
<td>In Vivo Evaluation, Labeling</td>
</tr>
<tr>
<td>Adverse tissue reaction</td>
<td>Biocompatibility, In Vivo Evaluation</td>
</tr>
<tr>
<td>Infection</td>
<td>Biocompatibility, Sterility, Shelf-Life Testing</td>
</tr>
<tr>
<td>Use error</td>
<td>Labeling</td>
</tr>
</tbody>
</table>

FDA believes that the following special controls, in addition to the general controls, address these risks to health and provide reasonable assurance of the safety and effectiveness:

1. The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use.
2. Performance testing must demonstrate deployment as indicated in the accompanying labeling, including the indicated introducer needles, and demonstrate expansion and resorption characteristics in a clinically relevant environment.
3. In vivo evaluation must demonstrate performance characteristics of the device including the ability of the plug to not prematurely resorb or migrate and the rate of pneumothorax.
4. Sterility testing must demonstrate the sterility of the device and the effects of the sterilization process on the physical characteristics of the plug.
5. Shelf-life testing must demonstrate the shelf-life of the device including the physical characteristics of the plug.
6. The device must be demonstrated to be biocompatible.
Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device and appropriate warnings. Labeling must include identification of compatible introducer needles.

Section 510(m) of the FD&C Act provides that FDA may exempt a class II device from the premarket notification requirements under section 510(k) of the FD&C Act if FDA determines that premarket notification is not necessary to provide reasonable assurance of the safety and effectiveness of the device. For this type of device, FDA has determined that premarket notification is necessary to provide reasonable assurance of the safety and effectiveness of the device. Therefore, this device type is not exempt from premarket notification requirements. Persons who intend to market this type of device must submit to FDA a premarket notification, prior to marketing the device, which contains information about the absorbable lung biopsy plug they intend to market.

II. Environmental Impact

The Agency has determined under 21 CFR 25.34(b) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

III. Paperwork Reduction Act of 1995

This final order establishes special controls that refer to previously approved collections of information found in other FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in part 807, subpart E regarding premarket notification submissions have been approved under OMB control number 0910-0120,
and the collections of information in 21 CFR part 801, regarding labeling have been approved under OMB control number 0910-0485.

IV. Reference

The following reference has been placed on display in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday, and is available electronically at http://www.regulations.gov.


List of Subjects in 21 CFR Part 878

Medical devices.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 878 is amended as follows:

PART 878--GENERAL AND PLASTIC SURGERY DEVICES

1. The authority citation for 21 CFR part 878 continues to read as follows:


2. Section 878.4755 is added to subpart E to read as follows:

§ 878.4755 Absorbable Lung Biopsy Plug.

(a) Identification. A preformed (polymerized) absorbable lung biopsy plug is intended to provide accuracy in marking a biopsy location for visualization during surgical resection and closure of pleural punctures associated with percutaneous, transthoracic needle lung biopsies. Upon deployment into the biopsy tract, the plug expands to fill the biopsy void and remains in place until resorbed.

(b) Classification. Class II (special controls). The special controls for this device are:
(1) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use.

(2) Performance testing must demonstrate deployment as indicated in the accompanying labeling, including the indicated introducer needles, and demonstrate expansion and resorption characteristics in a clinically relevant environment.

(3) In vivo evaluation must demonstrate performance characteristics of the device, including the ability of the plug to not prematurely resorb or migrate and the rate of pneumothorax.

(4) Sterility testing must demonstrate the sterility of the device and the effects of the sterilization process on the physical characteristics of the plug.

(5) Shelf-life testing must demonstrate the shelf-life of the device including the physical characteristics of the plug.

(6) The device must be demonstrated to be biocompatible.

(7) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device and appropriate warnings. Labeling must include identification of compatible introducer needles.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014-05061 Filed 03/07/2014 at 8:45 am; Publication Date: 03/10/2014]